Selwyn Ho

Outlook Microsoft Office 365 Google Cloud Hosting Viewpoint

immunotherapies & t cell receptors tcr biotechnology research immuno-oncology t cell receptor tcr-guided therapies 3s tcrs cancer elimination tcr-t therapies tcr-t cell engagers natural killer cell therapies precision immunotherapy patient-specific cancer treatment tumor microenvironment dendritic cell vaccines neoantigens pd1-41bb costimulatory switch proteins tcr discovery tcr optimization allogeneic tcr-nk therapies solid tumors tumor-specific antigens affinity tcrs immune evasion tumor antigen recognition biotechnology pharmaceutical development clinical validation partnerships cancer antigen targets high-throughput screening biopharmaceuticals drug modalities personalized cancer therapy immunotherapy pipeline antitumor activity immune monitoring therapeutic modalities tcr engineering research collaborations translational research cancer therapy innovation fda-approved therapies solid cancer treatments therapeutic interventions biotech partnerships cancer patient outcomes targeted therapy improvements tumor recognition mechanisms t cell receptor (tcr)-guided therapies cancer immunotherapy tcr-t cell therapies tcr-nk cell therapies end-to-end platform precision targeting cancer testis antigens clinical pipeline mdg1015 proprietary technologies tcr generation optimization product enhancement collaborations patient population gastric cancer ovarian cancer myxoid liposarcoma synovial sarcoma market share cancer treatment immune disorders corporate strategy r&d focus cash runway capital raise ind clearance patent filings